Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents

Allergic Reactions Clinical Trial

Official title:
A Single-Dose, Open-Label, Pharmacokinetic Study of Brompheniramine Maleate Liquid in Children and Adolescents

Status Completed

Clinical Trial Summary

The objective of this study is to characterize the pharmacokinetic (PK) profile of brompheniramine maleate (BROM) in children and adolescents, ages 2 to less than 18 years following dosing in accordance with current weight-age dosing guidelines. Once characterized, the PK data will be pooled with adult PK data from other studies and analyzed under a separate analysis plan to confirm or refine the existing OTC doses in children aged 2 to <12 yrs and adolescents aged 12 to <18 yrs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00894634
Study type	Interventional
Source	Wyeth is now a wholly owned subsidiary of Pfizer
Contact
Status	Completed
Phase	Phase 1
Start date	March 21, 2009
Completion date	April 26, 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01204866` - Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use	Phase 1
Completed	`NCT00195221` - Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B	Phase 4
Completed	`NCT00837837` - Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents	Phase 1